Aeon Biopharma Inc. is entering the next phase of development under a new chief executive following major setbacks for its lead drug candidate. The Irvine-based clinical-stage biopharmaceutical ...
Irvine-based Aeon Biopharma Inc. jumped 14% to $1.30 per share with a market cap of $18 million ahead of the biopharmaceutical firm’s FDA Type 2a meeting on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results